FDA Advisory Panel Votes Against MDMA-Assisted Therapy for PTSDFDA Roundup: Advisers Reject MDMA, Recommend New COVID-19 Vaccines / grandbrothers - stock.adobe.comAn independent FDA advisory panel voted against the use of midomafetamine (MDMA)-assisted therapy to treat post-traumatic stress disorder (PTSD) during a meeting held Tuesday. The advisory panel meeting was the first to review a psychedelic-assisted therapy in the United States. Although the FDA does not have to follow the committee’s vote, the federal agency does usually base its decision on it. Novavax Prepared to Deliver JN.1 Protein-based Non-mRNA COVID-19 Vaccine This Fall Consistent with U.S. FDA VRBPAC Recommendation. Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia.

Source: New York Times June 07, 2024 23:52 UTC